Assessment of Subclinical Cardiac Damage in Chronic Plaque Psoriasis Patients: a Case Control Study

Introduction: Epidemiological studies have suggested that patients with psoriasis are at an increased risk of developing cardiovascular diseases. Chronic inflammation may play a role in the pathogenesis of atherosclerosis in psoriasis patients. Recent studies have evaluated the expression of plasma endocan and homocysteine levels. Endocan is a marker of vascular endothelial damage, and homocysteine plays a role in the development of atherosclerosis. Plasma endocan and homocysteine levels, as well as echocardiographic parameters, were evaluated in patients with psoriasis to assess cardiovascular disease risk.

Material And Methods: This was a prospective cohort analysis of 40 patients who were diagnosed with psoriasis and 40 healthy controls matched to the patient group according to demographic and biochemical parameters.

Results: Serum endocan and homocysteine concentrations were significantly higher in the psoriasis group than the control group ( < 0.001). Serum endocan concentrations correlated positively with disease duration ( < 0.001; = 0.725). The Tei index (myocardial performance) was elevated in psoriasis patients ( < 0.001). Additionally, the E/A (mitral valve early diastolic peak flow velocity/mitral valve late diastolic peak flow velocity) and E/Em (early diastolic myocardial velocity) ratios were reduced in psoriasis patients ( < 0.001). Parameters indicative of left ventricular asynchrony were elevated significantly in the psoriasis group versus the control group ( < 0.001).

Conclusions: We observed a substantial increase in serum endocan and homocysteine concentrations, and significant differences in key parameters of cardiac function, in psoriasis patients relative to controls. These results are consistent with the hypothesis that subclinical cardiac damage is increased in patients with psoriasis and that psoriasis itself may be a cardiovascular risk factor.